Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

Davide Ciardiello

Citation

Annals of Oncology (2019) 30 (suppl_5): v1-v24. 10.1093/annonc/mdz238

Authors

D. Ciardiello1, V. Belli1, C. Cardone1, P.P. Vitiello1, G. Martini1, L. Poliero1, C. Borrelli1, G. Arrichiello1, V. Ciaramella1, N. Matrone1, G. Barra1, V. De Falco1, E.F. Giunta1, F. Morgillo1, T. Troiani1, M. Terminiello1, D. Melisi2, F. Ciardiello1, E. Martinelli1

Author affiliations

  • 1 Medicina Di Precisione, Università degli studi della Campania "Luigi Vanvitelli", 80131 - Naples/IT
  • 2 Medicina, AOU Integrata Verona "Borgo Roma", 37134 - Verona/IT
More

Resources

Abstract 3085

Background

AXL and transforming growth factor β (TGF-β) signalling pathways play a key role in modulating tumour microenvironment by promoting epithelial to mesenchymal transition (EMT), stromal activation and regulating immune response in colorectal cancer (CRC). Here we have evaluated the effect of double blockade of TGF-β and AXL receptors, as an innovative therapeutic strategy for CRC.

Methods

We assessed the correlation of TGF-β and AXL by an in silico analysis of a human CRC gene expression profile database. Afterwards, an evaluation of AXL expression of in a panel of human CRC cell lines by Western Blot (WB) and Real time PCR was performed. The sensitivity of HCT116 and LOVO cells to treatment with galunisertib (LY21209761), a TGF-β R1 inhibitor, and R428, an AXL inhibitor, was assessed by MTT, cell migration, and colony forming assays. Furthermore we generated patient derived 3D spheroid cultures from primary CRC, and tested their susceptibility to galunisertib and R428 by MTT assay. Finally, in vivo experiments were done with HCT116 and LOVO tumour xenografts in immunodeficient mice.

Results

In silico analysis showed an association between high expression levels of AXL and TGF-β R1 in CMS4 CRC. AXL was differently expressed on cell lines, and interestingly it resulted increased in HCT116 and LOVO after TGF-β inhibition, probably representing a mechanism of cancer cell escape. Dual blockade with galunisertib and R428 determined a reduction in cell migration of 50% in HCT116 and 37% in LOVO cells, respectively, and colony formation of approximately 90 % in both cell lines. Moreover, combined treatment displayed a strong synergistic activity in 3D cultures derived from five human CRC samples, resulting in the inhibition of proliferation ranging from 80 to 90%. The in vivo experiments of HCT116 and LOVO subcutaneous xenograft models are currently on going and results will be presented.

Conclusions

Combined TGF-β and AXL inhibition showed a promising activity in preclinical models of CRC and could represent a novel potential therapeutic strategy for patients with CRC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Università degli studi della Campania "Luigi Vanvitelli".

Funding

ICURE project, Università degli studi della Campania "Luigi Vanvitelli".

Disclosure

D. Melisi: Research grant/Funding (self): Lilly.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings